Cardiff Lexington’s losses jump 180.22% to $3,206,551 in third quarter
Key Facts
Cardiff Lexington reported a net loss of $3,206,551 for the three months ended September 30, 2026, an increase of $2,062,252, or 180.22%, from the loss in the same period of 2025. The company filed its quarterly report with the U.S. Securities and Exchange Commission on November 10, 2026. The wider loss coincided with lower revenue and gross profit compared with the year-earlier quarter. The chief executive said demand for the company’s services in its markets remained high. But he noted that working-capital constraints had limited the company’s ability to capitalize on opportunities.
Quarterly revenue was $1,912,179, compared with $3,058,740 for the three months ended September 30, 2025. Gross profit fell to $1,036,759 from $1,909,579 a year earlier. The company said the decline in revenue over the nine months was linked to a lower number of medical procedures and a lower implied collection rate from settlements of patient case claims. That rate fell from 44% at the start of 2025 to 42% in the first nine months of that year. It then declined to 40% as of September 30, 2026, according to the report.
On the expense side, interest expense rose to $2,468,536 in the third quarter, compared with $1,765,528 in the same period of 2025. The company attributed the increase mainly to higher upfront and additional fees related to draws and outstanding claims on the line of credit. Expenses paid as stock-based compensation also totaled $369,981, compared with $41,188 a year earlier. The chief executive reported that gross margin was 56.2% of revenue in the first nine months of 2026. The report cites these items alongside lower sales in explaining pressure on the company’s results.
The decline also extended to the nine months ended September 30, 2026, when revenue was $6,294,016, compared with $8,763,314 in the same period of 2025. The net loss for the period was $8,777,531, compared with $2,821,471 a year earlier. At the end of September, the company had cash of $584,319, while its accumulated deficit stood at $89,117,673. It recorded negative operating cash flow of $235,975 over the nine months. The company said these factors raise substantial doubt about its ability to continue as a going concern.
In a separate development before the results were published, the company’s shares closed at $0.01000 in the November 13, 2026, session, up 100% for the session, according to Investing.com data. The price ranged from $0.01000 to $0.01240 during the session, and trading volume was 169.84 thousand shares. The results were published on November 16, so the November 13 move does not represent a reaction to an announcement that had not yet been made. The company had said a letter of intent for a proposed transaction set a target closing date on or before November 16. But the letter did not bind the parties to complete the transaction and made it subject to due diligence, financing and definitive agreements, with a due diligence period of up to 45 days.
Cardiff Lexington said acceptance of the financing and investment terms had not ended negotiations, as due diligence and talks on transaction documents remained ongoing. It said these steps had extended the timeline previously expected for November 16. The company expects to make further progress in December 2026. But it did not set a deadline for signing an agreement, according to the results statement. Completion of the transaction remains subject to the relevant procedures and agreements being finalized.